Oncocyte Q2 net loss $8.3M; plans RIF to cut $4.5M annual costs

Insight Molecular Diagnostics Inc.

2023-Q2 EPS reported -$3.63 revenue$3,491,000

Net loss $8.3M ($0.07 EPS) vs $10.5M ($0.12 EPS) YoY; revenue $2.1M, flat.
Reduction in force to cut annual cash comp costs by >$4.5M; severance ~$2.0M in Q3 2022.
Closed underwritten offering of $32.8M and preferred stock offering of $4.9M in net proceeds.
Cash $47.1M as of June 30; annualized op expense reduction of ~$12M expected in 2023.
Appointed Gisela Paulsen President & COO and Anish John CFO, effective Aug 8, 2022.

item 2.02 item 2.05 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anish John

Chief Financial Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-08-08
Filed: August 10, 2022, 7:59 PM ET

Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.

Role change

Gisela Paulsen

President and Chief Operating Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-08-08
Filed: August 10, 2022, 7:59 PM ET

Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anish John was appointed as Chief Financial Officer at Insight Molecular Diagnostics Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gisela Paulsen was appointed as President and Chief Operating Officer at Insight Molecular Diagnostics Inc..

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

Effective August 8, 2022, the Board of Directors of the Company appointed Gisela Paulsen to the position of President and Chief Operating Officer and Anish John to the position of Chief Financial Officer.

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-021889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.